Pharmaceuticals

Lumosa to Initiate Phase 2 Human Clinical Trial in the US and Taiwan for Its LT3001, A Novel Drug for the Treatment of Acute Ischemic Stroke

TAIPEI, , June 13, 2019 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; code: 6535.TWO) announced that the company is ready to commence the Phase 2 proof of concept (PoC) study for its LT3001, a novel drug for the treatment of acute ischemic stroke (AIS) that showed good safety, tolerability and ...

2019-06-13 20:00 3823

CartiHeal Enrolls the 200th Patient in Its Pivotal Clinical Study in San Diego, CA

KFAR SABA, Israel, June 12, 2019 /PRNewswire/ -- CartiHeal, developer of the Agili-C™ implant for treating cartilage and osteochondral defects in traumatic and osteoarthritic joints, successfully enrolled the 200th patient in the Agili-C™ IDE pivotal clinical study. Surgery was performed byScott ...

2019-06-12 20:38 1492

Amcor Completes Acquisition of Bemis, Creating the Global Leader in Consumer Packaging

CHICAGO and MELBOURNE, Australia, June 11, 2019 /PRNewswire/ -- Amcor today announces the successful completion of its acquisition of Bemis Company Inc., effective11 June 2019. The combined company will now operate as Amcor plc (Amcor), trading on the New York Stock Exchange under the ticker symb...

2019-06-11 21:46 2118

Collaborative Medicinal Development, LLC Reports that Lead Drug Shows Dose-Dependent Improvement in Parkinson's Disease

MILL VALLEY, California, June 10, 2019 /PRNewswire/ -- Collaborative Medicinal Development LLC ("CMD"), a privately-held biopharmaceutical company developing innovative therapies for neurodegenerative diseases, will report promising results from its phase 1, non-placebo controlled, dose-finding s...

2019-06-10 20:00 1437

Sihuan's Abstracts regarding Clinical Trial Progress of SGLT-2 Inhibitor Selected for Poster Presentation at the American Diabetes Association's Scientific Sessions

HONG KONG, June 10, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular drug manufacturer in China's prescription drug market, announced that three abstracts regarding the clinical trial of the Group's patented innovative drug Janaglif...

2019-06-10 16:28 6298

CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib

SUZHOU, China, June 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced that the company has entered into a global clinical collaboration withChina focus with Bayer HealthCare LLC to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity ...

2019-06-10 09:30 6639

CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC

SUZHOU, China, June 5, 2019 /PRNewswire/ -- CStone Pharmaceuticals (CStone; HKEX: 2616) announced that it has received approval to initiate clinical development inChina of CS1001 in combination with BLU-554 (CS3008) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). T...

2019-06-05 19:56 6507

Ascentage Pharma presents new clinical data of apoptosis-targeted drug candidates APG-115 and APG-1387 at 2019 ASCO

SUZHOU, China and CHICAGO, June 3, 2019 /PRNewswire/ -- Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company presented new data of two apoptosis-ta...

2019-06-04 07:00 1864

Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa

Highlights: * 42% investigator-assessed ORR achieved in patients with advanced PEComa – a rare sarcoma with no currently approved therapy * First prospective clinical study in advanced PEComa shows durable responses with nab-sirolimus with a manageable safety profile * 62% of all responding...

2019-06-04 06:39 1869

CStone submits new drug application for TIBSOVO(R) in Taiwan for the treatment of relapsed/refractory AML

HONG KONG, June 2, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced that a new drug application (NDA) for TIBSOVO® (ivosidenib) has been submitted by a third-party to the Taiwan Food and Drug Administration (TFDA) as the first to-be-approved treatment of adult patients...

2019-06-03 11:45 5131

Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business

PHILADELPHIA, May 31, 2019 /PRNewswire/ -- Iovance Biotherapeutics, a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, has expanded its relationship with WuXi AppTec's Advanced Therapies Business Unit (WuXi ATU). Wu...

2019-05-31 20:00 1990

Conagen announces formation of Scientific Advisory Board

Board includes five world-leading scientists in the fields of Synthetic Biology and Applied Molecular Biology  BEDFORD, Massachusetts, May 30, 2019 /PRNewswire/ -- Conagen Inc., a vertically integrated synthetic biology and fermentation company, announced today the formation of a new scientific ...

2019-05-30 20:00 1683

CartiHeal's Agili-C™ Implant Enhances In-vitro Osteogenic Differentiation of Human Bone Marrow-derived Mesenchymal Stem Cells

KFAR SABA, Israel, May 30, 2019 /PRNewswire/ -- CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of osteochondral and chondral defects, announced today the publication of anin-vitro study demonstrating that the Agili-C™ implant enhances osteogenic differentiation of human...

2019-05-30 20:00 1638

Sihuan Pharm Obtained Phase I to III Clinical Trial Approval for the Third Generation of EGFR Inhibitor XZP-5809

HONG KONG, May 29, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular ("CCV") drug manufacturer inChina's prescription drug market, announced the third generation of EGFR inhibitor XZP-5809, a Category 1 innovative drug developed by t...

2019-05-29 18:00 4423

After $7.1 Billion Sale Of Frutarom, Ori Yehudai To Join The Sade Group As Active Chairman and Investor

NESS ZIONA, Israel, May 27, 2019 /PRNewswire/ -- Ori Yehudai: "I took a company worth$3 million and sold it to IFF at $7.1 billion in 2018. In my opinion, the success of our cannabis company will be to build an industrial pharmaceutical company with the strictest standards, we had two such plants...

2019-05-27 20:05 1829

Sihuan Pharm Becomes the First Chinese Company that was Granted Approval for "Non-PVC Solid-Liquid Double Chamber Bag for Ceftazidime/Sodium Chloride Injection"

HONG KONG, May 27, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Group"), the largest cardio-cerebral vascular ("CCV") drug manufacturer in China's prescription drug market, announced the "non-PVC solid-liquid double chamber bag for ...

2019-05-27 17:08 4421

111 to Collaborate with MSH to Build Internet Pharmaceutical and Healthcare Service Closed-loop System

SHANGHAI, May 24, 2019 /PRNewswire/ -- Following 111, Inc.'s (NASDAQ: YI) ("111" or the "Company") strategic partnership with Manulife-Sinochem last year, the Company has reached another milestone. OnMay 24, 111 and MSH, a world leader in the design and management of international healthcare solu...

2019-05-24 22:45 6819

Phebra establishes new subsidiary in Canada and announces marketing approval for its IV Arsenic Trioxide Solution

SYDNEY, May 23, 2019 /PRNewswire/ -- Australian pharmaceutical firm Phebra (the 'Company') has continued its international business expansion with the opening of its subsidiary inMontreal, Canada. The new entity, Phebra Canada, will be headed byTony Romagnino, Vice President of Phebra's current N...

2019-05-23 17:00 1184

China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province

TAIZHOU, China, May 22, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), announced today the laun...

2019-05-22 23:20 6176

Scientists Identify New Therapeutic Target for Fatty Liver Disease

* Preclinical study highlights a novel therapy for the treatment of fatty liver disease, which affects up to 25% of the global population * Inhibiting interleukin 11 (IL11) signalling addresses multiple aspects of non-alcoholic steatohepatitis (NASH), including hepatic inflammation and fibros...

2019-05-22 18:24 1224
12345678 ... 40